Bats may provide answers on Ebola
By Stacey Burling, Inquirer Staff Writer
Posted: August 13, 2014
When DeeAnn Reeder, a Bucknell University biologist, provoked the immune system of fruit bats, an odd thing happened.
Most animals that have been studied get a fever when injected with the portion of bacteria she used. The bats got colder.
"Bats are different," said Reeder, who studies them both here in Pennsylvania and in South Sudan, one of the places where Ebola first emerged.
There is a second vaccine underway with human testing in Md.
University of Maryland medical researchers are testing a vaccine developed at the National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health. It uses a chimpanzee cold virus that carries an Ebola protein. The viruses are genetically altered so they cannot reproduce, but the immune system nonetheless produces antibodies to counteract them.
"The more Ebola vaccines we can have, and the more we have data to see their advantages and disadvantages, the better," Levine said. "I hope we have multiple options to choose from."
Still, some question whether enough is being done to ensure that a vaccine will be mass-produced quickly. At an Ebola symposium hosted by the Johns Hopkins University Bloomberg School of Public Health last week, University of Minnesota epidemiologist Michael Osterholm suggested that the outbreak could explode if it reaches slums in more African cities or other continents. He called a widely distributed vaccine the best tool to stop it.
Because researchers cannot ethically expose human subjects to the Ebola virus, they instead have to compare the immune response to that of animal subjects, and, as much as possible, to the immune response of Ebola survivors.
Inovio has the animal data in hand and can produce the vaccine quickly so why are we still waiting?
SAN DIEGO, Oct. 14, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus. The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany. The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.
Prospectus also uses electroporation devices and they are in the spotlight recent funding from the gov.
Roche is involved with Inovio just not with Ebola at this point
every day brings new outbreaks and with it new interest in the companies that can produce the vaccines quickly
Although she did not come into direct contact with Thomas Eric Duncan - the Ebola-infected man who died of the disease - she may have had contact with clinical specimens collected from him
We need a new CDC head and a new leader of the free world.
Ebola scare on Caribbean cruise ship: Woman quarantined in her cabin after coming into contact with infected specimen from ‘patient zero’ at Texas hospital
The Gov f't up so bad there could be hundreds with Ebola and no one knows what to do.
How did he get on this plane
Fresh Ebola fears after a passenger flying from to Nigeria to JFK dies in his seat after vomiting profusely
UK pharmaceuticals firm GlaxoSmithKline says its Ebola vaccine will "come too late" for the current epidemic.
Not on humans yet
Under a one-year contract with Profectus BioSciences Inc., headquartered in Baltimore, ASPR’s
Biomedical Advanced Research and Development Authority (BARDA) will provide approximately $5.8
million in funding, in addition to subject matter expertise and technical assistance, to further develop an
experimental Ebola vaccine. The company will manufacture vaccine for use in animal safety studies and
future clinical trials and conduct animal studies to test safety. The contract can be extended to a total of
13 months and $8.6 million.
What if there's a push to speed these up because of all the recent CDC mistakes, which to date there are plenty of.
Multiple studies conducted by a team from the NIAID, CDC, FDA, and DoD have shown that a single dose of the Profectus VesiculoVax™ vectored Ebola and Marburg vaccines provides 100% protection of non-human primates against challenge with 1,000 times the lethal dose of both Ebola and Marburg viruses. A trivalent VesiculoVax™ vectored vaccine to protect against all filoviruses has entered non-human primate testing with financial support from the NIAID.
VesiculoVax™ Prophylactic Vaccines
for Public Health and Biodefense:
Ebola/Marburg | EEVs | Chikungunya | Lassa
That's exactly the illusion they want to project as they continue to harvest all the Ebola samples they can. What is the purpose of owning a patent, to make money. So why does the CDC own the Ebola patent? Would it be worth more as it spreads worldwide? Why is the incubation period of 21 days not accurate?
• 95% of Ebola incubations occur from 1 - 21 days
• 3% of Ebola incubations occur from 21 - 42 days
• 2% of Ebola incubations are not explained (why?)
Lewiston, Maine, has a large Somali Immigrant population.
The borders of Maine are just as easy to cross over from Canada.
Only a matter of time before such reports are true.
recent Ebola dosing in clinical trials
Cohort 1: 3x10(6)pfu VSV G-ZEBOV vaccine (BPSC1001) each dose, total volume 1 mL vs. placebo